Abbott snags MRI compatibility for implantable defibrillator

Abbott also markets a tiny MRI-compatible pacemaker, as well as MRI-compatible spinal cord stimulation systems, all picked up in its acquisition of St. Jude Medical.

The FDA approved MR-conditional labeling for the Ellipse implantable cardioverter defibrillator (ICD), a device it picked up in its $25 billion acquisition of St. Jude Medical. 

The approval covers the Ellipse ICD and its Tendril MRI pacing lead and Durata and Optisure high voltage leads. The new labeling opens up MRI scans as a diagnostic option for patients with abnormal heart rhythms who need treatment with an ICD. 

The Ellipse ICD is indicated for patients with ventricular tachycardia. Caused by misfiring electrical signals, the heart beats abnormally quickly and becomes unable to effectively pump blood. ICDs monitor a patient's heart rate and deliver impulses when an abnormal rhythm is detected. If this isn't enough, the device "shocks" the heart to restore rhythm. 


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

RELATED: St. Jude bags CE mark for MRI-compatible pacemaker 

"When you consider the number of patients each year who rely on the lifesaving treatment delivered by an ICD device, it is critical to continually innovate to provide new benefits to people battling complex arrhythmias and other cardiac conditions," said Mark Carlson, M.D., chief medical officer for Abbott's Cardiac Arrhythmias and Heart Failure unit. "By expanding our portfolio of MRI compatible devices, we're adding another benefit onto an ICD device that was designed hand-in-hand with physicians to optimize therapy for patients." 

Earlier this year, Abbott had MRI-conditional labeling approved for its Assurity pacemaker, also gained in the St. Jude deal. The Assurity device is the smallest and longest-lasting MRI-compatible device of its kind. Before the acquisition, St. Jude had notched a series of MRI-conditional labels for its devices, including its Proclaim and Protégé spinal cord stimulation systems. 

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The National Institutes of Health has tapped the genomics firm Color to help participants understand and act on their results.

In a $72 million deal, Inex Innovations Exchange and Nova Satra will combine their laboratory, R&D and distribution arms.